Drug Interaction Guidance for Mycophenolate Mofetil

Known Interacting Medications

• Aluminum/magnesium hydroxide‑containing antacids reduce the oral bioavailability of mycophenolate mofetil, necessitating dose modification (based on FDA prescribing information) 1.

Contraindications with Related Antimetabolites

• Concurrent use of allopurinol with azathioprine is contraindicated because it can cause fatal bone‑marrow suppression (reported in transplant guidelines) 1.

Safety of Clindamycin Co‑administration

• Clindamycin may be co‑administered with mycophenolate mofetil without routine dose adjustment or additional monitoring beyond standard protocols (expert clinical summary) [2][3].

Standard Monitoring Recommendations (Applicable Regardless of Clindamycin Use)

• Perform a complete blood count with differential at baseline, 2–3 weeks after mycophenolate initiation, and then every 3 months during maintenance therapy (standard transplant monitoring) 3.
• Hold or reduce mycophenolate mofetil if the absolute neutrophil count falls below 1.3 × 10³ cells/µL (safety threshold in transplant practice) 3.